In vivo low density lipoprotein oxidation relates to coronary reactivity in young men

Journal of the American College of Cardiology

Volumn 30, Issue 1, 1997, Pages 97-102

  Raitakari, Olli T ^a   Pitkänen, Olli Pekka ^a   Lehtimäki, Terho ^b,c   Lahdenperä, Sanni ^d   Iida, Hidehiro ^e   Ylä Herttuala, Seppo ^f   Luoma, Jukka ^f   Mattila, Kari ^g   Nikkari, Tapio ^b   Taskinen, Marja Riitta ^d   Viikari, Jorma S A ^a   Knuuti, Juhani ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e RESEARCH INSTITUTE FOR BRAIN AND BLOOD VESSELS AKITA   (Japan)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; LIPID ANALYSIS; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; AUTOANTIBODIES; CHOLESTEROL, LDL; CORONARY CIRCULATION; CORONARY VESSELS; DIPYRIDAMOLE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPID PEROXIDATION; MALE; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED; VASODILATOR AGENTS;

EID: 0343247773     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00103-4     Document Type: Article

References (51)

1. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1993;801-809.
2. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation. 84:1991;1273-1278.
3. Reddy KG, Nair NR, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 23:1994;833-843.
4. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation. 90:1994;808-817.
5. Czernin J, Barnard J, Sun KT, et al. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation. 92:1995;197-204.
6. Pitkänen O-P, Raitakari OT, Niinikoski H, et al. Coronary flow reserve is impaired in young men with hypercholesterolemia. J Am Coll Cardiol. 28:1996;1705-1711.
7. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary arteries. J Clin Invest. 86:1990;75-79.
8. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Circulation. 92:1995;1582-1589.
9. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 86:1989;1372-1376.
10. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
11. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 14:1994;32-40.
12. Clark J, Crouzel C, Meyer G, Strijckmans K. Current methodology for oxygen-15 production for clinical use. Appl Radiat Isot. 38:1987;597-600.
13. Crouzel C, Clark J, Brihaye C, et al. Radiochemistry automation for PET. Stöcklin G, Pike V. Radiopharmaceuticals for Positron Emission Tomography. 1993;45-90 Kluwer, Dordrecht, The Netherlands.
14. Iida H, Kanno I, Takahashi A, et al. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography strategy for quantification in relation to the partial-volume effect . Circulation. 78:1988;104-115.
15. Iida H, Takahashi A, Tamura Y, Ono Y, Lammertsma A. Myocardial blood flow comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation . J Nucl Med. 36:1995;78-85.
16. Viikari J. Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation. Scand J Clin Lab Invest. 36:1976;265-268.
17. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
18. Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
19. Heitzer T, Ylä-Herttuala S, Luoma J, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia role of oxidized LDL . Circulation. 93:1996;1346-1353.
20. Parthasarathy S, Fong LG, Otero D, Steinberg D. Recognition of solubilized apoproteins from delipidated oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc Natl Acad Sci USA. 84:1987;537-540.
21. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gel electrophoresis. Meth Enzymol. 128:1986;417-431.
22. Rainwater DL, Andres DW, Ford AL, Lowe WF, Blanche PJ, Krauss RM. Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. J Lipid Res. 33:1992;1876-1881.
23. Lahdenperä S, Puolakka J, Pyörälä T, Luotola H, Taskinen M-R. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. Atherosclerosis. 122:1996;153-162.
24. SAS/STAT User's Guide release 6.03 ed . 1988;SAS Institute Inc, Cary (NC).
25. Czernin J, Müller P, Chan S, et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation. 88:1993;62-69.
26. Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol. 14:1989;639-652.
27. Araujo LI, Lammertsma AA, Rhodes CG, et al. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation. 83:1991;875-885.
28. Uren NG, Marraccini P, Gistri R, de Silva R, Camici PG. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol. 22:1993;650-658.
29. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary artery stenosis. N Engl J Med. 330:1994;1782-1788.
30. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol. 15:1990;1032-1042.
31. Rosen SD, Uren NG, Kaski J-C, Tousoulis D, Davies GJ, Camici PG. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation. 90:1994;50-60.
32. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
33. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:1990;160-162.
34. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
35. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
36. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 250:1986;H822-H827.
37. Yokoyama M, Hirata K, Miyake R, Akita H, Ishikawa Y, Fukuzaki H. Lysophosphatidylcholine essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein . Biochem Biophys Res Commun. 168:1990;301-308.
38. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG. Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb. 14:1994;1007-1013.
39. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am J Physiol. 267:1994;H2441-H2449.
40. Yang X, Cai B, Sciacca RR, Cannon PJ. Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ Res. 74:1994;318-328.
41. Galle J, Bassenge E, Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res. 66:1990;1287-1293.
42. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol modifications of low density lipoprotein that increase its atherogenicity . N Engl J Med. 320:1989;915-924.
43. Maggi E, Chiesa R, Melissano G, et al. LDL oxidation in patients with severe carotid atherosclerosis a study of in vitro and in vivo oxidation markers . Arterioscler Thromb. 14:1994;1892-1899.
44. Bui MN, Sack MN, Moutsatsos G, et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J. 131:1996;663-667.
45. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation . J Hypertens. 13:1995;129-138.
46. Rubanyi G, Romero J, Vanhoutte P. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol. 240:1986;H1145-H1149.
47. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 94:1993;350-356.
48. DeGraaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 11:1991;298-306.
49. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 93:1992;189-199.
50. Jansen H, Ghanem H, Kuypers JH, Birkenhager JC. Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B. Atherosclerosis. 115:1995;255-262.
51. Swinkels DW, Demacker PNM, Hendricks JCM, van't Laar A. Low density lipoprotein subfractions and relationships to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis. 9:1989;604-613.